Shalabh Singhal

Shalabh Singhal has a strong background in the pharmaceutical and healthcare industries. Their most recent role is as the Chief Medical Officer at Salubris Biotherapeutics starting in 2023. Prior to that, they worked at Bristol Myers Squibb from 2014 to 2023 where they held various positions, including Vice President: Development Program Lead and Executive Director: Development Program Lead. In these roles, they led large multidisciplinary teams and was responsible for all aspects of drug development across multiple indications and therapeutic areas. Shalabh managed budgets, ensured timely execution, and oversaw protocol development and trial operations. Shalabh also had experience in clinical trial lead roles and worked on global Phase 2 studies and IND filings. Prior to joining Bristol Myers Squibb, Singhal worked as a Non-invasive Cardiologist at Mercer Bucks Cardiology in 2013 and as an Invasive Cardiologist at Community Health Network from 2010 to 2013. Shalabh also had a role as a Cardiologist at Johnson Memorial Hospital from 2010 to 2013. Singhal's expertise and experience span both medical and leadership roles in the healthcare and pharmaceutical sectors.

Shalabh Singhal has a Bachelor of Science degree in Chemistry from Canisius College. Shalabh also holds a Doctor of Medicine (M.D.) degree from State University of New York Upstate Medical University. Additionally, Singhal has completed an Internal Medicine Residency Program at Jefferson Health. Shalabh has also participated in a Cardiovascular Disease Fellowship Program at the University of Cincinnati. Singhal is certified by the American Board of Internal Medicine in Cardiology. The specific dates of their education and the year they obtained their certification are not provided.